Patents Examined by Alicia L Otton
  • Patent number: 11987569
    Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: May 21, 2024
    Assignee: BIONTECH SE
    Inventor: Christophe Henry
  • Patent number: 11980626
    Abstract: The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders or symptoms thereof.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: May 14, 2024
    Assignee: Kembi Therapeutics Pty Ltd
    Inventors: Edwina Baskin-Bey, Joel Eisner, Elizabeth Woodson
  • Patent number: 11970470
    Abstract: Compounds for treating preventing malaria and, particularly, to larvicidal agents that are {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones derivatives and their use as larvicidal agents.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: April 30, 2024
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Rashmi Venugopala
  • Patent number: 11963954
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: April 23, 2024
    Assignees: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
  • Patent number: 11957683
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: April 16, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan, Yannick Debing
  • Patent number: 11957680
    Abstract: Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 16, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Patent number: 11958814
    Abstract: A 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 16, 2024
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11952381
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: April 9, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
  • Patent number: 11944619
    Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: April 2, 2024
    Assignee: SRX Cardio, LLC
    Inventors: Thomas E. Barta, Jonathan William Bourne, Kyle D. Monroe, Michael M. Muehlemann, Anjali Pandey, Simeon Bowers
  • Patent number: 11939336
    Abstract: The present disclosure concerns synthesis, anion binding features, liquid-liquid extraction of salts, and anti-corrosion character of aryl-triazole bicyclic macrocycles of Formula (I) and related compounds:
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 26, 2024
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Amar H. Flood, Yun Liu, Wei Zhao
  • Patent number: 11919838
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: March 5, 2024
    Inventors: Eric Anderson, Xin Jiang, Melean Visnick
  • Patent number: 11919865
    Abstract: Provided herein are improved processes for the preparation of a compound of Formula IX (AG-10). Also provided herein are pharmaceutically acceptable salts of Formula I and Formula Ib as well as crystalline types of Formula IX (AG-10). The processes described herein provide improved yields and efficiency, while the pharmaceutically acceptable salts and crystalline forms provide unexpected pharmacokinetic properties. Other features and aspects of the present disclosure will be apparent to a person of skill in the art upon reading the remainder of the specification.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: March 5, 2024
    Inventors: Pooran Chand, Yogesh Kumar Gupta, Rakesh Kumar Kumawat, Mamoun Alhamadsheh, Robert Zamboni
  • Patent number: 11911397
    Abstract: The present invention provides methods and compositions for treating cancer, reducing side effects, and reducing postmenopausal symptoms comprising anordrin or analog thereof (such as anordrin) alone or in combination with at least one other agent selected from the group consisting of tamoxifen, raloxifene or functional equivalent thereof, and an aromatase inhibitor.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: February 27, 2024
    Inventors: Jun Yang, Huijuan Shi, Wenping Xu
  • Patent number: 11912669
    Abstract: The present invention relates to compositions and methods for the treatment of cancer and other diseases associated with mitochondrial dysfunction, including but not limited to, neurodegenerative disease, brain injuries, and certain non-neurological disorders, using a novel compound, 6-chloro-3-(2,4-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4(3H)-one, and derivatives thereof.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: February 27, 2024
    Assignee: Cerepeut, Inc.
    Inventor: Bingwei Lu
  • Patent number: 11912711
    Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: February 27, 2024
    Inventors: Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Jane Panteleev, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu, Maxence Bos, John Mancuso, Ivan Franzoni
  • Patent number: 11911371
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: February 27, 2024
    Assignee: NOVARTIS AG
    Inventors: Urs Baettig, Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark Le Grand, Katrin Spiegel
  • Patent number: 11904022
    Abstract: A carrier-free nanoparticle based on the self-assembly of curcumin-erlotinib conjugate (EPC) that exhibits stronger cell killing, better anti-migration effects, and anti-invasion effects for pancreatic cancer cells than the combination of free curcumin and erlotinib.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 20, 2024
    Inventor: Peisheng Xu
  • Patent number: 11897843
    Abstract: The present invention relates to a process for the preparation of enantiomerically enriched 3-aminopiperidine, as in particular of its R-enantiomer (R)-3-aminopiperidine. The invention also relates to an enantiomerically enriched intermediate of said process and to specific acid-addition salts of 3-aminopiperidine (hereinafter also APIP) that are useful for obtaining a single enantiomer of APIP, and to crystalline (R)-3-aminopiperidine-dihydrochloride-monohydrate and crystalline (S)-3-aminopiperidine-dihydrochloride-monohydrate.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: February 13, 2024
    Inventors: Karl Reuter, Tobias Wedel, Viktor Meier, Mark Kantor, Vasyl Andrushko, Florian Stolz
  • Patent number: 11891367
    Abstract: Method for preparing 3,7-bis(dimethylamino)phenothiazin-5-ylium iodide, the method resulting in a high purity while being very simple to implement and producing high yields. The method uses phenothiazine as a starting material and includes the following steps: a) treating phenothiazine with diiodine, b) treating the reaction medium directly obtained from step a) with dimethylamine.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: February 6, 2024
    Inventors: Michel Feraud, Babak Sayah, Stéphane Queru, Marina Laurent
  • Patent number: 11884666
    Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: January 30, 2024
    Assignee: Alcon Inc.
    Inventors: David Ellis, Howard Allen Ketelson